Intract

Finch Therapeutics and Intract Pharma Announce Collaboration to Enable Targeted Delivery of Microbial Communities

he Phloral technology will enable the first-in-human discovery approach at Finch. "Phloral is an exciting technology for our research into the microbiome because it enables oral delivery of communities with the same precise targeting as traditional but less convenient colonoscopic delivery,” says Dean Glettig, Director of Product Development at Finch.